IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Impax Asset Management Group plc

Impax Asset Management Group plc trimmed its position in IQVIA Holdings Inc. (NYSE:IQV) by 88.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 201,203 shares of the medical research company’s stock after selling 1,591,807 shares during the quarter. Impax Asset Management Group plc owned 0.11% of IQVIA worth $39,538,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. FMR LLC raised its stake in shares of IQVIA by 38.7% in the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock valued at $684,213,000 after acquiring an additional 804,963 shares during the period. JPMorgan Chase & Co. raised its position in IQVIA by 46.2% in the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock valued at $437,378,000 after purchasing an additional 583,396 shares during the period. Nordea Investment Management AB boosted its position in shares of IQVIA by 47.4% in the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after buying an additional 452,029 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of IQVIA by 3.4% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,226,083 shares of the medical research company’s stock valued at $290,545,000 after buying an additional 39,772 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. lifted its position in IQVIA by 2.6% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,049,912 shares of the medical research company’s stock worth $206,318,000 after acquiring an additional 26,648 shares in the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director John G. Danhakl purchased 1,275 shares of the firm’s stock in a transaction on Tuesday, December 3rd. The stock was bought at an average cost of $200.58 per share, for a total transaction of $255,739.50. Following the completion of the acquisition, the director now directly owns 1,275 shares of the company’s stock, valued at approximately $255,739.50. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 1.60% of the company’s stock.

Analysts Set New Price Targets

IQV has been the subject of several analyst reports. Stifel Nicolaus decreased their target price on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Deutsche Bank Aktiengesellschaft cut their target price on IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. UBS Group dropped their price target on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Stephens began coverage on shares of IQVIA in a report on Friday, December 20th. They set an “overweight” rating and a $250.00 price objective for the company. Finally, Morgan Stanley upped their price objective on IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a research note on Tuesday, February 11th. Four analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $251.22.

IQVIA Trading Down 1.6 %

Shares of IQV stock opened at $190.94 on Monday. IQVIA Holdings Inc. has a fifty-two week low of $187.62 and a fifty-two week high of $261.73. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The stock has a 50-day simple moving average of $199.57 and a 200 day simple moving average of $216.25. The stock has a market capitalization of $33.62 billion, a P/E ratio of 25.46, a P/E/G ratio of 1.99 and a beta of 1.48.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, sell-side analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.